78
Key facts: <a href="https://firmsworld.com/novo-nordisk/" title="Novo Nordisk Profile: 2025 A Comprehensive Guide - FirmsWorld" target="_blank" rel="noopener">Novo Nordisk</a> stock rises 9.12%; expands diabetes partnership; launches Ozempic ad campaign — TradingView News
- Novo Nordisk ADR (NVO) saw a stock price increase of 5.21, closing at 62.33, which reflects a percentage gain of 9.12%. The trading volume reached 43,098,749 shares.1
- Novo Nordisk has expanded its partnership with Aspect Biosystems to develop diabetes treatments, acquiring rights to key technologies for producing insulin-making islet cells from stem cells.234
- Novo Nordisk launched a new ad campaign for Ozempic, starring Justin Long and John Hodgman, emphasizing its FDA approvals for chronic kidney disease and cardiovascular risk reduction.5
